Dexcom [DXCM] vs Boston Scientific [BSX] Detailed Stock Comparison

Dexcom Inc.

NASDAQ
Loading...

Boston Scientific Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Dexcom Inc. wins in 8 metrics, Boston Scientific Corporation wins in 11 metrics, with 0 ties. Boston Scientific Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Dexcom Inc. Boston Scientific Corporation Better
P/E Ratio (TTM) 30.03 27.49 Boston Scientific Corporation
Price-to-Book Ratio 8.63 4.02 Boston Scientific Corporation
Debt-to-Equity Ratio 50.85 48.92 Boston Scientific Corporation
PEG Ratio 0.39 0.29 Boston Scientific Corporation
EV/EBITDA 19.85 19.85 Dexcom Inc.
Profit Margin (TTM) 17.94% 17.29% Dexcom Inc.
Operating Margin (TTM) 25.64% 21.55% Dexcom Inc.
EBITDA Margin (TTM) 25.64% 21.55% Dexcom Inc.
Return on Equity 34.50% 11.84% Dexcom Inc.
Return on Assets (TTM) 8.89% 6.64% Dexcom Inc.
Free Cash Flow (TTM) $1.08B $3.40B Boston Scientific Corporation
1-Year Return -8.07% -52.97% Dexcom Inc.
Price-to-Sales Ratio (TTM) 5.10 4.74 Boston Scientific Corporation
Enterprise Value $23.09B $107.72B Boston Scientific Corporation
EV/Revenue Ratio 4.95 5.23 Dexcom Inc.
Gross Profit Margin (TTM) 62.93% N/A N/A
Revenue per Share (TTM) $12 $14 Boston Scientific Corporation
Earnings per Share (Diluted) $2.05 $2.39 Boston Scientific Corporation
Beta (Stock Volatility) 1.56 0.78 Boston Scientific Corporation
Short % of Float 4.93% 1.58% Boston Scientific Corporation

Dexcom Inc. vs Boston Scientific Corporation Stock Performance Analysis

Loading Price Chart...

DXCM
BSX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dexcom Inc.-1.53%-3.13%20.43%11.88%12.92%11.54%
Boston Scientific Corporation-0.32%-3.98%-11.24%-33.00%-49.28%-50.63%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dexcom Inc.-8.07%-42.07%-27.92%315.26%2,149.85%2,129.88%
Boston Scientific Corporation-52.97%-13.64%9.04%108.58%590.87%133.50%

Performance & Financial Health Analysis: Dexcom Inc. vs Boston Scientific Corporation

MetricDXCMBSX
Market Information
Market Cap i$23.76B$97.63B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i4,652,60418,916,072
90 Day Avg. Volume i4,100,84816,730,711
Last Close$74.22$46.76
52 Week Range$54.11 - $89.98$45.99 - $109.50
% from 52W High-17.52%-57.30%
All-Time High$164.86 (Nov 15, 2021)$109.50 (Sep 09, 2025)
% from All-Time High-54.98%-57.30%
Growth Metrics
Quarterly Revenue Growth0.13%0.12%
Quarterly Earnings Growth0.76%0.99%
Financial Health
Profit Margin (TTM) i0.18%0.17%
Operating Margin (TTM) i0.26%0.22%
Return on Equity (TTM) i0.35%0.12%
Debt to Equity (MRQ) i50.8548.92
Cash & Liquidity
Book Value per Share (MRQ)$7.14$16.34
Cash per Share (MRQ)$5.19$1.32
Operating Cash Flow (TTM) i$1.44B$4.50B
Levered Free Cash Flow (TTM) i$719.54M$10.53B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Dexcom Inc. vs Boston Scientific Corporation

MetricDXCM (Apr 26, 2026)BSX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i30.0327.49
Forward P/E i20.5917.29
PEG Ratio i0.390.29
Price to Sales (TTM) i5.104.74
Price to Book (MRQ) i8.634.02
Market Capitalization
Market Capitalization i$23.76B$97.63B
Enterprise Value i$23.09B$107.72B
Enterprise Value Metrics
Enterprise to Revenue i4.955.23
Enterprise to EBITDA i19.8519.85
Risk & Other Metrics
Beta i1.560.78
Book Value per Share (MRQ) i$7.14$16.34

Financial Statements Comparison: Dexcom Inc. vs Boston Scientific Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricDXCM (2025)BSX (2025)
Revenue/Sales i4.66B20.07B
Cost of Goods Sold i1.86B6.22B
COGS % of Revenue i39.9%31.0%
Gross Profit i2.80B13.85B
Gross Margin i60.1%69.0%
Research & Development i599.10M2.05B
Operating Income (EBIT) i911.80M3.97B
Operating Margin i19.6%19.8%
EBITDA i1.36B5.33B
EBITDA Margin i29.1%26.6%
Pre-Tax Income i1.09B3.39B
Pre-Tax Income % of Revenue i23.3%16.9%
Income Tax i252.10M493.00M
Income Tax % of Revenue i5.4%2.5%
Net Income (Profit) i836.30M2.89B
Profit Margin i17.9%14.4%

Balance Sheet & Liquidity Metrics

MetricDXCM (2025)BSX (2025)
Cash & Equivalents i917.70M1.97B
Total Current Assets i4.03B8.79B
Total Current Assets % of Revenue i86.5%43.8%
Total Current Liabilities i2.14B5.44B
Total Current Liabilities % of Revenue i46.0%27.1%
Long-Term Debt i1.37B11.14B
Long-Term Debt % of Revenue i29.3%55.5%
Total Shareholders Equity i2.75B24.47B
Retained Earnings i2.43B5.57B
Retained Earnings % of Revenue i52.2%27.8%
Property, Plant & Equipment i77.40M0

Cash Flow Statement Comparison

MetricDXCM (2025)BSX (2025)
Operating Cash Flow i1.48B4.50B
Operating Cash Flow % of Revenue i31.7%22.4%
Capital Expenditures i-363.50M-876.00M
Free Cash Flow i1.08B3.40B
FCF Margin i23.1%17.0%
Debt Repayment i-1.21B-2.05B
Common Stock Repurchase i-500.00MN/A

Short Interest & Institutional Ownership Analysis

MetricDXCMBSX
Shares Short i14.72M23.53M
Short Ratio i3.771.59
Short % of Float i4.93%1.58%
Shares Outstanding i384.80M1.49B
Float Shares i382.94M1.48B
% Held by Insiders i0.28%0.21%
% Held by Institutions i101.50%95.16%
% Held by Public i-1.78%4.63%

Dividend Analysis & Yield Comparison: Dexcom Inc. vs Boston Scientific Corporation

MetricDXCMBSX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A